Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’s “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

Telomir Pharmaceuticals, Inc. reported new preclinical data from an in vivo study in mice bearing human aggressive prostate cancer tumors evaluating DNA-methylation changes in two key defense genes – CASP8 and GSTP1 – following treatment with oral Telomir-1, Rapamycin, chemotherapy, and combination regimens.